Glaxo (GSK) Presents Phase III Data on Sirukumab & Benlysta

GlaxoSmithKline plc GSK reported results from two pivotal phase III studies SIRROUND T and SIRROUND H on subcutaneous sirukumab anti interleukin 6 monoclonal antibody for the treatment of adults with moderate to severely active rheumatoid arthritis RA SIRROUND T evaluated